UCB SA (OTCMKTS:UCBJY – Get Free Report) traded up 6.1% on Wednesday. The company traded as high as $121.16 and last traded at $121.16. Approximately 3,002 shares traded hands during trading, a decline of 93% from the average daily volume of 40,709 shares. The stock had previously closed at $114.20.
Analysts Set New Price Targets
Several analysts have issued reports on UCBJY shares. Zacks Research cut UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 16th. Jefferies Financial Group upgraded UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on UCBJY
UCB Trading Down 2.5%
The business has a fifty day moving average price of $120.84 and a two-hundred day moving average price of $135.15.
UCB Company Profile
UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.
UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.
Read More
- Five stocks we like better than UCB
- Steel Dynamics Eyes New Highs Despite Earnings Miss
- SpaceX Earnings Launch: High Margins Fund AI Ambitions
- 2 Steel Giants Just Reported Earnings—and Told Very Different Stories
- Swiping to Record Highs: Why Visa Remains a Fortress
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
